| US 7,528,169 B2 | ||
| Substance having antitumor/anti-inflammatory activity | ||
| Hiroyuki Osada, Saitama (Japan); Hideaki Kakeya, Saitama (Japan); Hiroshi Konno, Akita (Japan); and Susumu Kanazawa, Kanagawa (Japan) | ||
| Assigned to Riken, Saitama (Japan) | ||
| Appl. No. 10/498,341 PCT Filed Dec. 16, 2002, PCT No. PCT/JP02/13124 § 371(c)(1), (2), (4) Date Mar. 18, 2005, PCT Pub. No. WO03/051804, PCT Pub. Date Jun. 26, 2003. |
||
| Claims priority of application No. 2001-382539 (JP), filed on Dec. 17, 2001. | ||
| Prior Publication US 2005/0176824 A1, Aug. 11, 2005 | ||
| Int. Cl. A61K 31/225 (2006.01); C12P 7/02 (2006.01); C12P 7/18 (2006.01); C07C 69/00 (2006.01); C07C 39/18 (2006.01) | ||
| U.S. Cl. 514—548 [435/155; 435/158; 560/144; 568/780] | 6 Claims |
1. A compound represented by the following formula (I) or a salt thereof:
 wherein R1 represents an alkyl group, an alkenyl group, or —CO—R3 (wherein R3 represents an alkyl group, an aryl group, or an alkylamino group); R2 represents formyl group, —CH2—OCOR4 (wherein R4 represents an alkyl group, an aryl group, or an alkylamino group), —CH2—O—R5 (wherein R5 represents an alkyl group, or an alkenyl group), —CH2═N—O—R6 (wherein R6 represents hydrogen atom or an alkyl group), or CH2═CH—R7 (wherein R7 represents an alkyl group, an alkyloxycarbonyl group, formyl group, or an alkyloxycarbonylalkenyl group).
|